Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Por Heng, D. Y., MacKenzie, M. J., Vaishampayan, U. N., Bjarnason, G. A., Knox, J. J., Tan, M. H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B. I., Choueiri, T. K.
Publicado em 2012

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Por Heng, D. Y. C., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., Srinivas, S., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Vaishampayan, U. N., Tan, M. H., Rha, S. Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L. A.
Publicado em 2014

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Por Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Publicado em 2014